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NKT cell subsets can be divided based on CD4 and NK1.1 expression
and tissue of origin, but the developmental and functional rela-
tionships between the different subsets still are poorly under-
stood. A comprehensive study of 19 cytokines across different NKT
cell subsets revealed that no two NKT subpopulations exhibited
the same cytokine profile, and, remarkably, the amounts of each
cytokine produced varied by up to 100-fold or more among
subsets. This study also revealed the existence of a population of
CD4NK1.1 NKT cells that produce high levels of the proinflam-
matory cytokine IL-17 within 2–3 h of activation. On intrathymic
transfer these cells develop into mature CD4NK1.1 but not into
CD4NK1.1 NKT cells, indicating that CD4NK1.1 NKT cells in-
clude an IL-17–producing subpopulation, and also mark the elusive
branch point for CD4 and CD4 NKT cell sublineages.
cytokines  CD1d  thymus  T cell
NKT cells are CD1d-dependent T cells that mediate potentimmunoregulatory functions in settings of autoimmunity, can-
cer, infection, and tolerance (1). Mouse NKT cells express the T cell
antigen receptor (TCR) V14J18 chain coupled with V8.2, V7,
or V2, whereas human NKT cells have V24J18 coupled to
V11 (2). The biological function of NKT cells is paradoxical,
because they rapidly produce large amounts of both T helper type
1 (Th1) and Th2 cytokines and promote cell-mediated immunity in
some settings but suppress cell-mediated immunity in others (1).
One explanation for how NKT cells mediate these diverse
functions is the existence of functionally distinct subsets. NKT cells
can be divided broadly into CD4 and CD4 subsets (2). In
humans, this classification provides an important functional dis-
tinction, because CD4 NKT cells make both Th1 and Th2 cyto-
kines (such as IFN-, TNF, IL-4, IL-10, IL-13), whereas CD4NKT
cells primarily make Th1 cytokines (IFN- and TNF) (1, 3, 4).
Mouse NKT cells also include CD4 and CD4 subsets, but no
clear distinction in cytokine production has been identified. This is
surprising, because mouse CD4 and CD4 NKT cells are distinct
in their ability to regulate immune responses in vivo (5). However,
careful subset analyses of NKT cell cytokine production in mice
have been limited largely to IFN- and IL-4 production (5); these
analyses are inadequate, because NKT cells are known to produce
many other cytokines, including IL-5, GM-CSF, TNF, IL-10, IL-13,
IL-21, and IL-17 (1, 6–8).
IL-17 production by NKT cells is particularly interesting. A
relatively new lineage of differentiated effector CD4 T cells (Th17
cells) is defined by IL-17 production, and these cells play a critical
role in the onset and progression of some forms of cell-mediated
autoimmunity (9, 10). Differentiation of Th17 cells can occur in the
presence of certain cytokine combinations, including TGF- and
IL-6 or TGF- and IL-21 (9, 10). Th17 cells also up-regulate the
IL-23 receptor, and IL-23 is important in Th17 expansion and
maintenance (10). The master transcriptional regulator of Th17
development is RORt; Th17 cells fail to develop in its absence,
whereas its overexpression enhances Th17 development (11). It is
unclear whether IL-17 production by NKT cells requires or is
enhanced by the same differentiation signals, nor is it clear which
subset of NKT cells produces this cytokine. Although Michel et al.
(8) showed that NK1.1 NKT cells were the primary producers of
IL-17, these cells were poor producers of IFN- and IL-4. This
finding contrasts with our own data showing that NK1.1NKT cells
in the periphery are capable of potent IFN- and IL-4 produc-
tion (12).
Herein, we investigate the cytokine-producing capability of NKT
cell subsets. We demonstrate remarkable heterogeneity among
NKT cell subsets and show that a previously unstudied subset of
CD4NK1.1 NKT cells is the main source of NKT-derived IL-17.
Furthermore, transfer of thymic CD4NK1.1 NKT cells to fetal
thymus organ culture (FTOC) generates CD4 but not
CD4NK1.1 NKT cells, demonstrating that these cells represent
the elusive branch point of the CD4 and CD4 NKT cell subsets.
Results
Extreme Diversity in Cytokine Production by Distinct NKT-Cell Popu-
lations. NKT cell subpopulations defined by CD4 and NK1.1
expression were isolated from thymus, spleen, and liver and were
tested for their ability to produce cytokines over a range of time
points after stimulation with plate-bound anti-CD3/CD28 in vitro.
These included IFN-, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10,
IL-13, IL-17, IL-21, GM-CSF and TNF (Fig. 1); macrophage
inflammatory protein (MIP-1), Regulated upon Activation, Nor-
mal T cell Expressed and Secreted (RANTES) [supporting infor-
mation (SI) Fig. S1]; IL-12, Monocyte Chemotactic Protein-1
(MCP-1), Monokine Induced by IFN-gamma (MIG), and Kera-
tinocyte Chemokine (KC) were assayed also but were not detected
(data not shown). Cytokine amounts are depicted on a logarithmic
scale. Generally, thymus-derived NKT cells were by far the most
potent cytokine producers (Fig. 1). In a notable exception, at 72 h
the production of IFN- by liver-derived NKT cells was comparable
to or higher than the production of IFN- by thymic NKT cells. This
was confirmed by intracellular cytokine staining (ICS), which
showed a higher percentage of IFN- cells from the liver fraction
than from the thymus fraction at this time point (Fig. 2).
In separate experiments in which NKT cell subsets were stimu-
lated by using -GalCer–pulsed DC (Fig. S2), cytokine production
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by thymus NKT cell subsets was much lower, but the responses by
peripheral NKT cells to the two types of stimulation were approx-
imately comparable. A possible explanation is that a much higher
proportion of thymic NKT cells express inhibitory receptors (13–
15) that dampen NKT cell cytokine production when engaged by
their ligands on the DC (16). Conversely, spleen CD4NK1.1
NKT cells showed higher cytokine production in response to
-GalCer–pulsed DC stimulation than to CD3/CD28 ligation,
suggesting that spleen NKT cells have a greater requirement for
DC-derived factors such as IL-12 and IL-18. Because of the
differential regulatory mechanisms at play in these cultures, we
favor data from CD3/CD28-stimulated NKT cells, because these
cultures reveal the potential of each NKT subset to produce
cytokines.
The most dramatic differences in anti-CD3/CD28 cultures were
observed when comparing NK1.1 and NK1.1 NKT cells (Fig. 1),
particularly those from the thymus. In addition to higher IL-4 and
lower IFN- levels that have been documented previously (17, 18),
thymus NK1.1 NKT cells also produced substantially more IL-17,
IL-10, and IL-21 but less IL-2, IL-3, IL-6, IL-9, GM-CSF, TNF,
MIP-1, and RANTES. Peripheral NK1.1 NKT cells generally
were less active than their thymic counterparts, particularly at the
20-h time point, which is consistent with these cells being distinct
populations of cells (12). By 72 h, however, cultures of peripheral
NK1.1 NKT cells had accumulated levels of some cytokines
(including IL-2, IL-4, IL-10, IL-13, IL-17, IL-21, IFN-, TNF, and
MIP-1) similar to or exceeding those of their thymic counterparts,
suggesting slower induction and/or more sustained production. This
was supported by ICS of NK1.1 NKT cells at the 72-h time point,
showing that more liver NK1.1 NKT cells than thymic NK1.1
NKT cells were producing IFN- and IL-17 (Fig. 2). In contrast to
human NKT cell subsets in which CD4 NKT cells produce higher
levels of Th2 cytokines (3, 4), we found that mouse CD4NK1.1
NKT cells and CD4NK1.1NKT cells generally were comparable
in their ability to produce IL-4 in response to anti-CD3/CD28; if
anything, CD4NK1.1 NKT cells in thymus and liver were more
potent producers of IL-10 and IL-13 (Fig. 1). The most striking
difference between the CD4 and CD4 subsets was IL-17 pro-
duction, which was restricted almost entirely to the CD4NKT cell
fraction in each tissue tested.
NK1.1 NKT Cells Constitutively Express IL-23R and RORt. Given that
Th17 development depends on expression of RORt (11) and
IL-23R (10), we investigated the expression of these factors by NKT
cell subsets to determine whether they correlated with IL-17–
producing capacity (Fig. 3). Quantitative RT-PCR analysis of
thymic NKT cell subsets showed that both factors were constitu-
tively expressed by NK1.1NKT cells and, to a lesser extent, by
CD4NK1.1 NKT cells, whereas CD4NK1.1 NKT cells and
naı¨ve conventional T cells showed little or no expression of these
factors. The level of expression of these factors either did not
change, or decreased, after activation in vitro.
CD4NK1.1 NKT Cells Are the Major Source of IL-17. Most, but not
all, NK1.1 NKT cells in the thymus and liver express CD4. Given
Fig. 1. Distinct cytokine production by NKT cell subsets. NKT cells from spleens, livers, and thymuses of B6 mice were identified as -GC/CD1d tetramer TCR
cells and divided further on the basis of NK1.1 and CD4 expression as shown in the upper right dot plot (shown is a representative thymus sample). Purified NKT
subsets were cultured in wells coated overnight with 10g/ml anti-CD3 and 10g/ml anti-CD28. An aliquot of supernatant was harvested at 24 and 72 h to assay
for secreted cytokines. IL-17 and IL-21 were assayed by ELISA. All other cytokines were assayed by cytometric bead array. The absence of bars indicates
undetectable amounts of cytokine, unless ‘‘not done’’ is stated. For thymus and liver NKT subsets, the results are derived from 5 or 6 separate cultures collected
over three independent experiments. For spleen NKT cell subsets, results are derived from 3 or 4 separate cultures collected over two independent experiments.
Bars depict mean  standard error. All cytokine values are expressed in ng/ml. Total cells  absolute cell number.
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that production of IL-17 in the NK1.1 fraction of NKT cells was
restricted largely to CD4 cells, we investigated whether CD4 cells
were responsible for IL-17 production in the NK1.1 fraction. We
first used ICS on sorted NKT cell subsets and confirmed our
hypothesis that the CD4 fraction of NK1.1 NKT cells was much
more capable of IL-17 production compared with the CD4
fraction (Fig. 4A). We next sorted thymus- and liver-derived
NK1.1 NKT cells into CD4 and CD4 subsets to test them
independently for IL-17 secretion (Fig. 4B). The CD4NK1.1
NKT cells produced at least 10 times more IL-17 than the
CD4NK1.1 cells, and after 24 h thymus-derived cells were the
most potent source of this cytokine. Similar results were observed
in the liver: the CD4NK1.1 NKT subset was the main source of
IL-17, although optimal IL-17 production by liver-derived NKT
cells seemed to be delayed compared with the thymus. The pres-
ence of IL-17 in the supernatants of the NK1.1CD4 NKT cell
cultures at 24 h suggested IL-17 was produced rapidly after stim-
ulation. Indeed, ICS of NKT cells just 6 h after anti-CD3/28
stimulation showed very clear IL-17 production by 28% of
CD4NK1.1NKT cells but by2% of the CD4NK1.1 fraction
(Fig. 4C).
An interesting observation was that not all cells within the
CD4/NK1.1-defined subsets were producing cytokines by ICS (Fig.
2 and Fig. 4). This may in part reflect the strength or timing of the
in vitro stimulus so that not all cells were activated to the same
extent. However, the exclusive production of IL-17 and IFN- by
different cells also suggests that the subsets we have defined may be
further divisible.
We also examined IL-17 production from lymph node, spleen,
and lung lymphocytes after short-term (3 h) stimulation with
Phorbol myristate acetate (PMA) and ionomycin, which supported
our observations from the thymus and liver that IL-17–producing
NKT cells were primarily NK1.1CD4 (Fig. S3). Using an intra-
thymic FITC injection assay to track recent thymic emigrants, we
found that recent thymic emigrant NKT cells were readily detect-
able in spleen, as published (18), but were almost undetectable in
lymph nodes, where NKT cell production of IL-17 is most abundant
(data not shown). This finding suggests that peripheral IL-17–
producing NK1.1 NKT cells are part of the mature NKT cell pool
rather than immature thymic emigrant cells. It is noteworthy that in
these experiments NKT cells were not separated according to
NK1.1 expression before stimulation, excluding the possibility that
NK1.1 ligation somehow inhibits IL-17 production by the NK1.1
fraction.
The finding that RORt is constitutively expressed by some NKT
cells suggests that these cells are primed to make IL-17, because
transduction of RORt into naı¨ve CD4 T cells has been shown to
elicit IL-17 production (11). Nonetheless, we tested whether NKT
cells were susceptible to regulation via traditional Th17-inducing
factors. Inhibition of IFN- and IL-4 augmented NKT cell expan-
sion and IL-17 production within the NKT cell compartment (Fig.
S4). Addition of TGF- and IL-6 did increase the percentage of
NKT cells producing IL-17, and CD4NKT cells made up a higher
proportion of these cells. However, these factors impaired the
recovery of NKT cells from these cultures, and hence their net
effect on IL-17 production by NKT cells seemed to be negligible.
Given the differences in IL-17 production between
CD4NK1.1 and CD4NK1.1NKT cells, these subsets also were
tested separately for production of other cytokines (Fig. S5). In
general, CD4NK1.1 and CD4NK1.1 NKT subsets had similar
cytokine profiles and resembled each other more closely than they
resembled their NK1.1 counterparts. Except for IL-17, which was
produced at higher levels by CD4NK1.1 NKT cells, the thymic
CD4NK1.1 fraction produced the same or higher levels of
cytokines (IFN-, IL-4, IL-6, IL-10, IL-13) than the thymic
CD4NK1.1 NKT cells. Liver CD4NK1.1 and CD4NK1.1
NKT cells also produced similar levels of cytokines, except for
IL-17.
CD4NK1.1 NKT Cells Are Precursors to the CD4NK1.1 Lineage. It
is known that CD4NK1.1NKT cells in the thymus are immature
precursors that can differentiate into NK1.1 NKT cells when
transferred into a thymus in vitro or in vivo (17–19), but it is not
known whether this ability also extends to CD4NK1.1 cells.
Therefore, we added carboxyfluorescein diacetate succinimidyl
ester (CFSE)-labeled CD4 and CD4NK1.1 NKT cells to sep-
arate NKT cell development cultures (12). Both subsets showed
clear precursor potential in terms of their higher proliferation
(CFSE dilution) and generated NK1.1NKT cells within a week of
intrathymic culture. However, CD4NK1.1 NKT cells generated
CD4NK1.1 cells, whereas CD4NK1.1 cells preferentially gen-
erated CD4NK1.1 cells (Fig. 5). When mature CD4NK1.1
Fig. 2. Costaining of NKT cell subsets for IFN- and IL-17. NKT cell subsets
were isolated and stimulated on anti-CD3– and anti-CD28–coated plates as
described in Fig. 1. GolgiStopTM was added to cultures 4 h before the indicated
time point, and cells were stained for intracellular IFN--APC and IL-17-PE.
Numbers in each quadrant represent the percentage of cells in that quadrant,
and results are representative of two independent experiments.
Fig. 3. Constitutive expression of RORt and IL-23R by NK1.1 NKT cells. NKT
cells were isolated from thymuses of B6 mice, separated into CD4NK1.1,
CD4NK1.1, and NK1.1 fractions, and stimulated for 20 or 72 h on anti-CD3/
CD28–coated plates as in Fig. 1. Naı¨ve T cells (CD4/CD62L/CD44lo/CD25) also
were purified from spleen, and Th-17 cells were generated from naı¨ve spleen
after 3-d culture on anti-CD3–coated plates in the presence of TGF-, IL-6,
anti-IFN-, anti-IL-4, and 1g/ml soluble anti-CD28. RNA was isolated from all cell
preparations, and expression of RORt and IL-23R was determined relative to 18S
ribosomal RNA. No stimulation and 20-h bars represent a total of 2 or 3 separate
samples collected over two independent experiments, and 72-h bars represent
4–6 separate samples collected over three independent experiments. Bars depict
mean standard error.









NKT cells were added to this thymus differentiation system, they
proliferated less and remained mostly (90%) CD4NK1.1 (data
not shown), consistent with our earlier finding that these cells
remain CD4 after intrathymic transfer in vivo (19). Taken to-
gether, this indicates that the elusive branch point for CD4 NKT
cells occurs before NK1.1 up-regulation.
Immature NK1.1 NKT cells can be subdivided further into
CD44low and CD44hi cells. When we analyzed these for CD4
expression, we found that in 1-week-old mice, the CD4NK1.1
NKT cells were enriched for the more mature CD44hi cells (Fig. 5).
Although this was less clear in 4-week-old mice, the intensity of
CD44 expression still seemed to be higher in the CD4NK1.1
subset than in the CD4NK1.1 subset. These data suggested that
CD4NK1.1 NKT cells branch at a very early stage in NKT cell
lineage development, just before or at the time CD44 up-regulation
is starting to occur.
Discussion
Although it is well established that human NKT cell subsets, based
on CD4 and CD8 expression, are functionally diverse in terms of
cytokine production (3, 4), it is not clear whether similar diversity
exists for mouse NKT cells. In this study, we have analyzed mouse
NKT cell subsets based on the expression of CD4, NK1.1, and the
tissue source. After examining different NKT cell subpopulations
from thymus, spleen, and liver for production of 19 cytokines, our
results show that mouse NKT cell populations exhibit remarkable
diversity, with differences of 10- to 100-fold in the extent to which
most cytokines were produced in response to anti-CD3/CD28
stimulation. Moreover, ICS suggested that further subpopulations
exist, because IL-17 and IFN- production seemed to be mutually
exclusive, even within the NK1.1 or CD4NK1.1 subsets. Al-
though there were many interesting differences that should form
the subject of future investigations into NKT cell diversity, the most
intriguing finding was the potent production of IL-17 by
CD4NK1.1 NKT cells.
Rapid IL-17 release by CD4NK1.1 NKT cells may have
important physiological consequences. Whereas Th17 cells gener-
ally are recognized as being the main source of IL-17 during
immune responses (10), Th17 cells are differentiated effector CD4
T cells that develop from naı¨ve CD4 T cells in the presence of
cytokines such as TGF-, IL-6, IL-21, and IL-23 over a matter of
days. NKT cells, however, can produce IL-17 within 3 h and may
therefore be a very important initial source of this proinflammatory
cytokine. Consistent with this concept, Michel et al. demonstrated
that lung NKT cells contributed to IL-17–dependent airway neu-
trophilia in response to LPS/-GalCer instillation (8). However, in
contrast to Michel et al., who showed that NK1.1 NKT cells
produced IL-17 but not IFN- or IL-4, our results showed that the
NK1.1 NKT cells do produce IFN- and IL-4. It is important to
point out that our findings that NK1.1 NKT cells also produce
IFN- and IL-4 are consistent with all other studies of this subset
(e.g., refs. 12, 17, 18). These contrasting results may reflect different
modes of stimulation, although in our experiments -GalCer–
pulsed DC, anti-CD3/CD28, and PMA/ionomycin were all capable
of stimulating potent IL-17, IFN-, and IL-4 production by liver
NK1.1NKT cells. It also is conceivable that NKT cell exacerbation
of some autoimmune diseases including collagen-induced arthritis
(20, 21) and experimental autoimmune encephalomyelitis (22) are
Fig. 4. IL-17 is produced primarily by a rare population of NK1.1CD4 NKT cells. (A) Purified NKT cell populations from thymus and liver were stimulated as
described in Fig. 1, and ICS was performed after 20 and 72 h. The first group of dot plots shows freshly isolated NKT cells for -GC/CD1d tetramer and CD4
expression. The second and third groups represent cultured cells at 20 and 72 h, respectively, and depict CD4 versus IL-17. The numbers in each quadrant represent
the percentage of total cells, except for stimulated NK1.1NKT cells, for which the numbers represent the percentage of either CD4or CD4NKT cells producing
IL-17. Dot plots are representative of two experiments. (B) NKT cells from thymus and liver were purified into 4 subsets on the basis of NK1.1 and CD4 expression
and cultured as described in Fig. 1. Supernatants were harvested at 24 and 72 h to assay for secreted IL-17 by ELISA. Thymus bars represent 8 separate cultures
derived over four independent experiments, and liver bars represent 3–5 separate cultures derived over two independent experiments. The 24-h thymus graph
contains a split y-axis. (C) NK1.1CD4 and NK1.1CD4 thymus NKT cells were assayed for intracellular IL-17 expression after 6 h CD3/CD28 stimulation in 1
experiment. Shown is IL-4 versus IL-17 expression in stimulated and nonstimulated samples. Numbers represent the percentage of cells in that quadrant.
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mediated via NKT cell production of IL-17, which is known to be
a key factor in these diseases (10).
In line with the ability of NKT cells to produce IL-17 rapidly,
RORt and IL-23 receptor (IL-23R) were constitutively expressed
by NK1.1 NKT cells. This finding is odd, considering that IL-23R
generally is found on highly differentiated T cells including Th17
and memory T cells. Furthermore, a previous study using an EGFP
reporter system suggested that RORt is not expressed by NKT
cells (23). It is not easy to reconcile this with our data, except that
on close inspection it is apparent that a very small subset of NKT
cells is positive for EGFP (23), which may correlate with
CD4NK1.1 NKT cells, which represent5% of total NKT cells
in the adult thymus.
Collectively, thymic NK1.1 NKT cells have been considered to
be immature precursors to their NK1.1 counterparts, but the
branching of CD4 and CD4 NKT cells has proven difficult to
define. Most NK1.1 NKT cells are CD4, but the dramatic
difference in IL-17 production by CD4NK1.1 NKT cells and
CD4NK1.1 cells prompted us to assay their developmental
potential separately. The results revealed that CD4NK1.1 NKT
cells are precursors to the CD4NK1.1 lineage, meaning that the
branch point for these cells occurs before NK1.1 up-regulation
(which we previously have referred to as ‘‘control point 2’’) (24).
The earliest NKT cells are defined as CD24, and all these cells are
NK1.1CD4 (25). As thymic NKT cells mature, they lose CD24
expression and up-regulate CD44 and NK1.1. Our data suggest that
the CD4 branch point in NKT cells occurs before or during the
transition from CD44lo to CD44hi within the NK1.1 stage (Fig. 6),
because CD4NK1.1 NKT cells vary in CD44 expression. How-
ever, given that, at least in 1-week-old mice, a larger proportion of
CD4NK1.1 NKT cells than CD4NK1.1 NKT cells express
CD44, these cells may be slightly more mature. This slight increase
in maturity may explain their lower production of IL-4 and other
cytokines that were expressed at high levels by the broader NK1.1
subset (17). Although the molecular basis for the divergence of
CD4 NKT cells remains unclear, the marked difference in pro-
duction of IL-17 by CD4 and CD4 NKT cells, combined with
other studies indicating their functional divergence (5), supports the
concept that two separate sublineages of NKT cells diverge at the
CD44loNK1.1 stage, during intrathymic NKT cell development.
In addition to subset-specific IL-17 production, we also demon-
strated that NKT cells are remarkably heterogeneous for an array
of other cytokines. Although the type of stimulation (anti-CD3/
CD28 versus -GalCer–pulsed DC) had some bearing on the
cytokine profiles of some NKT cell subsets, the key point remains
that different NKT cell subsets produce remarkably diverse cyto-
kine profiles.
Our data raise the question whether distinct cytokine profiles
reflect different roles/functions for specific NKT cell subsets in
immune responses. Few models have compared distinct NKT
subsets directly, but we have shown that liver-derived NKT cells are
superior to NKT cells from other organs in promoting tumor
rejection and that CD4NK1.1 NKT cells from liver promote
tumor rejection more effectively than CD4NK1.1 liver NKT cells
(5). This is interesting in light of the current data that anti-CD3/
28–stimulated liver NK1.1NKT cells produce high levels of IFN-
but only low levels of Th2 cytokines such as IL-4, IL-10, and IL-13.
Although thymus-derived NKT cells produce similar amounts of
IFN-, the higher potential production of IL-4, IL-10, and IL-13 by
these cells may explain why they could not promote tumor rejection.
Consistent with this, inhibition of IL-4 and IL-10 improved the
ability of NKT cells from thymus and liver to promote tumor
rejection (5). Differential production of the proinflammatory cy-
tokine IL-17 by CD4 and CD4 liver NKT cells also may explain
why the CD4 NKT cells are more potent in models of tumor
rejection (5). Although studies that have explored the effect of
IL-17 on tumor immunity have generated equivocal results (26),
there is some evidence that this cytokine can enhance T cell–
mediated tumor rejection (27, 28).
In summary, we have demonstrated that mouse NKT cell sub-
populations exhibit remarkable diversity in their ability to produce
cytokines. In particular, the production of the proinflammatory
cytokine IL-17 by mouse CD4NK1.1 cells, and to a lesser extent
by CD4NK1.1 NKT cells, sharply distinguishes these cells from
CD4 NKT cells. The characterization of CD4NK1.1 NKT cells
also adds a new subpopulation to the NKT cell family and, at least
for these cells in the thymus, provides a ‘missing link’ that represents
Fig. 5. CD4NK1.1 NKT cells are precursors for CD4NK1.1 NKT cells. (A)
E15 fetal thymus lobes were cultured for 1 week in standard FTOC conditions
to allow development of CD4CD8 thymocytes. Lobes then were added to
hanging drop cultures, combined with defined NKT subsets overnight, and
returned to standard FTOC conditions for another 7 days before harvesting for
analysis by FACS. CFSE labeling or a congenic marker together with-GC/CD1d
tetramer staining was used to identify donor NKT cells, and both doublet
exclusion and unloaded tetramer exclusion were used to exclude false posi-
tives. Data are representative of 10 separate cultures for CD4NK1.1NKT cell
repopulations and of 9 CD4NK1.1NKT cell repopulations derived over three
independent experiments. (B) The percentage of mature NKT cell subsets from
the given starting population that is present at the end of the culture period.
Bars depict mean  standard error. (C) NKT cells defined as -GC/CD1d
tetramer TCR cells were electronically gated, and NK1.1 and NK1.1
subsets were examined separately for expression of CD44 versus CD4. Data
shown are representative of 5 separate mice for each time point.
Fig. 6. Revised schematic of NKT cell development showing CD4 NKT cells
branching at the NK1.1 stage.









the branch point for CD4 NKT lineage. Although this study
represents a major step toward understanding NKT cell functional
diversity and development, it raises important new questions about
these cells: What is the developmental signal that results in branch-
ing of the CD4 lineage at the NK1.1 stage? Do the mutually
exclusive IL-17 and IFN- subsets of CD4NK1.1 NKT cells
represent distinct lineages, and do they both contain precursor
potential? What is the relationship between similar (CD4/NK1.1-
defined) subsets with distinct cytokine profiles in different tissues?
What is the molecular basis for the extremely diverse cytokine
profiles? Do the different subsets perform distinct functions asso-
ciated with their unique cytokine profiles? The most important
message from this study is that, as with conventional T cells and
dendritic cells, studies into NKT cell biology and function must
examine these cells as individual subpopulations, because they are
too diverse to be examined as a homogeneous lineage.
Materials and Methods
Mice. C57BL/6 mice were bred in house at the Department of Microbiology and
Immunology Animal Facility, University of Melbourne, Australia. All mice used
were between 5 and 7 weeks old unless otherwise stated, and all experiments
were conducted in accord with the animal ethics guidelines of the University of
Melbourne Animal Ethics Committee.
Lymphocyte Isolation. Lymphocytes were isolated from the liver, thymus, and
spleen as described in ref. 5. Thymic NKT cells were enriched from thymus by
labeling thymocytes with anti-CD8 (clone 3.155) and anti-CD24 (J11D), and
tagged cells were depleted by using rabbit complement (C-SIX Diagnostics) in the
presence of DNase (Roche Diagnostics). Cells were spun over a histopaque gra-
dient (1.083 g/ml; Sigma–Aldrich) at room temperature to collect viable cells. NKT
cells were enriched from spleen by staining with phycoerythrin (PE)-conjugated
CD1d tetramer and subsequent incubation with anti-PE microbeads (Miltenyi
Biotech). Labeled cells then were passed through a magnetic column using the
Miltenyi AUTOMACS system, and magnetized cells were collected and washed
before being labeled for flow cytometric purification.
Antibodies and Flow Cytometry. All antibodies used were from BD PharMingen.
Antibodies included TCR-FITC (clone H57–597), NK1.1-PE/CY7 (PK-136), CD4-
APC/CY7 (RM4–5), IL-17-PE (TC11–18H10), IL-4-APC (11B11), and CD44 FITC (IM7).
Mouse CD1d tetramer loaded with -GalCer (kindly provided by Kirin Pharma
Company) was produced in house, using recombinant baculovirus encoding
His-tagged mouse CD1d and mouse 2-microglobulin originally provided by M.
Kronenberg (La Jolla Institute for Allergy and Immunology, San Diego, CA). For
ICS, cells were cultured in GolgiStop (BD Biosciences) before being fixed and
permeabilized by using the BD Cytofix/Cytoperm Plus Fixation/Permeabilization
Kit. Flow cytometry was performed by using either an LSR-II or FACSCanto, and
purification was performed on a FACSAria (BD Biosciences). Analysis was per-
formed by using FlowJo software (Tree Star Inc.).
Cytokine Analysis from Cell Culture Supernatants. All cytokines were assayed by
using BD Biosciences cytometric bead array flex set for mice (IL-2, IL-3, IL-4, IL-5,
IL-6, IL-9, IL-10, IL-12, IL-13, IFN-, TNF, MIP-1, Monocyte Chemotactic Protein-1,
Monokine Induced by IFN-gamma, Keratinocyte Chemokine, and RANTES) ex-
cept for IL-17 and IL-21, which were detected by using ELISA from R&D Systems.
Captureanddetectionantibodies intheIL-21ELISAkitwereusedat0.8g/ml (2
recommended concentration), and IL-17 ELISA reagents were used as recom-
mended.
Cell Culture. For each experiment, tissues were pooled from 10–20 mice before
NKT cells were purified and cultured separately. Cells were cultured in tissue
culture media (as described in SI Methods) in a 96-well plate. For in vitro stimu-
lation assays, no-azide low-endotoxin anti-CD3 (145–2C11; BD PharMingen) and
anti-CD28 (37.51; BD PharMingen) were used at a concentration of 10 g/ml to
coat plates. For -GalCer/DC and NKT cell cocultures, DCs were pulsed with
200-ng/ml-GalCer for 3 h and washed twice before being mixed with NKT cells.
Fetal ThymusOrgan Culture. Thymic lobes were removed from embryos at day 15
of gestation and cultured for 7 days on the surface of filters (pore size, 0.45 m)
resting on Gelfoam sponges (Amersham Pharmacia) placed (and previously
soaked) in 1 ml of FTOC medium (refer to SI Methods). After culture, the lobes
were placed in Terasaki plates, 2 lobes per well, containing sorted and CFSE-
labeled (as described in ref. 12) populations of NKT cells in 30 l of RPMI-FTOC
medium. The Terasaki plates were inverted gently, forming a hanging drop, and
were incubated overnight. The lobes then were returned to standard FTOC
conditions and cultured for 7 days in 1-ml cultures in RPMI-FTOC. Lobes were
disrupted carefully using glass coverslips to release the cells for FACS analysis.
ACKNOWLEDGMENTS. We thank Alice Denton and Dr. Stephen Turner for help
withquantitativeRT-PCR,KenFieldforflowcytometric support,andDavidTaylor
for animal husbandry. This research was funded by National Health and Medical
Research Council (NHMRC) Program Grant 251608, renewed as 454569. J.M.C.
and L.A.P. are supported by Cancer Research Institute postgraduate scholarships.
S.C. and S.P.B. are supported by NHMRC Career Development Awards. F.M. is
supportedbyanNHMRCDoraLushPostgraduateFellowship.D.I.G.andM.J.S.are
supported by NHMRC Research Fellowships. We also thank the Picchi Brothers
Foundation for generous contributions to the Flow Cytometry Facility.
1. Godfrey DI, Kronenberg M (2004) Going both ways: Immune regulation via CD1d-
dependent NKT cells. J Clin Invest 114:1379–1388.
2. Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L (2004) NKT cells:
What’s in a name? Nat Rev Immunol 4:231–237.
3. Gumperz JE, Miyake S, Yamamura T, Brenner MB (2002) Functionally distinct subsets of
CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J Exp Med
195:625–636.
4. Lee PT, Benlagha K, Teyton L, Bendelac A (2002) Distinct functional lineages of human
V(alpha)24 natural killer T cells. J Exp Med 195:637–641.
5. Crowe NY, et al. (2005) Differential antitumor immunity mediated by NKT cell subsets
in vivo. J Exp Med 202:1279–1288.
6. Coquet JM, et al. (2007) IL-21 is produced by NKT cells and modulates NKT cell
activation and cytokine production. J Immunol 178:2827–2834.
7. Harada M, et al. (2006) IL-21-induced B epsilon cell apoptosis mediated by natural killer
T cells suppresses IgE responses. J Exp Med 203:2929–2937.
8. Michel ML, et al. (2007) Identification of an IL-17-producing NK1.1(neg) iNKT cell
population involved in airway neutrophilia. J Exp Med 204:995–1001.
9. Ivanov II, Zhou L, Littman DR (2007) Transcriptional regulation of Th17 cell differen-
tiation. Semin Immunol 19:409–417.
10. Weaver CT, Hatton RD, Mangan PR, Harrington LE (2007) IL-17 family cytokines and the
expanding diversity of effector T cell lineages. Annu Rev Immunol 25:821–852.
11. Ivanov II, et al. (2006) The orphan nuclear receptor RORgammat directs the differen-
tiation program of proinflammatory IL-17 T helper cells. Cell 126:1121–1133.
12. McNab FW, et al. (2007) Peripheral NK1.1 NKT cells are mature and functionally distinct
from their thymic counterparts. J Immunol 179:6630–6637.
13. Robson MacDonald H, Lees RK, Held W (1998) Developmentally regulated extinction
of Ly-49 receptor expression permits maturation and selection of NK1.1 T cells. J Exp
Med 187:2109–2114.
14. Uldrich AP, et al. (2005) NKT cell stimulation with glycolipid antigen in vivo: Costimu-
lation-dependent expansion, bim-dependent contraction, and hyporesponsiveness to
further antigenic challenge. J Immunol 175:3092–3101.
15. Voyle RB, et al. (2003) Ligand-dependent inhibition of CD1d-restricted NKT cell devel-
opment in mice transgenic for the activating receptor Ly49D. J Exp Med 197:919–925.
16. Maeda M, Lohwasser S, Yamamura T, Takei F (2001) Regulation of NKT cells by Ly49:
Analysis of primary NKT cells and generation of NKT cell line. J Immunol 167:4180–4186.
17. Benlagha K, Kyin T, Beavis A, Teyton L, Bendelac A (2002) A thymic precursor to the NK
T cell lineage. Science 296:553–555.
18. Pellicci DG, et al. (2002) A natural killer T (NKT) cell developmental pathway involving
a thymus-dependent NK1.1() CD4() CD1d-dependent precursor stage. J Exp Med
195:835–844.
19. McNab FW,etal. (2005) The influence of CD1d in postselection NKT cell maturation and
homeostasis. J Immunol 175:3762–3768.
20. Chiba A, Kaieda S, Oki S, Yamamura T, Miyake S (2005) The involvement of V(alpha)14
natural killer T cells in the pathogenesis of arthritis in murine models. Arthritis Rheum
52:1941–1948.
21. Ohnishi Y, et al. (2005) TCR Valpha14 natural killer T cells function as effector T cells in
mice with collagen-induced arthritis. Clin Exp Immunol 141:47–53.
22. Jahng AW, et al. (2001) Activation of natural killer T cells potentiates or prevents
experimental autoimmune encephalomyelitis. J Exp Med 194:1789–1799.
23. Egawa T, et al. (2005) Genetic evidence supporting selection of the valpha14i NKT cell
lineage from double-positive thymocyte precursors. Immunity 22:705–716.
24. Godfrey DI, Berzins SP (2007) Control points in NKT-cell development.NatRev Immunol
7:505–518.
25. Benlagha K, Wei DG, Veiga J, Teyton L, Bendelac A (2005) Characterization of the early
stages of thymic NKT cell development. J Exp Med 202:485–492.
26. Langowski JL, Kastelein RA, Oft M (2007) Swords into plowshares: IL-23 repurposes
tumor immune surveillance. Trends Immunol 28:207–212.
27. Benchetrit F, et al. (2002) Interleukin-17 inhibits tumor cell growth by means of a
T-cell-dependent mechanism. Blood 99:2114–2121.
28. Hirahara N,et al. (2001) Inoculation of human interleukin-17 gene-transfected Meth-A
fibrosarcoma cells induces T cell-dependent tumor-specific immunity in mice. Oncol-
ogy 61:79–89.
11292  www.pnas.orgcgidoi10.1073pnas.0801631105 Coquet et al.
Supporting Information
Coquet et al. 10.1073/pnas.0801631105
SI Methods
Tissue Culture Media.RPMI medium 1640 supplemented with 100
units/ml penicillin, 100 g/ml streptomycin, 2 mM Glutamax, 1
mM sodium pyruvate (Invitrogen Life Technologies), 0.1 mM
nonessential amino acids (Invitrogen Life Technologies), 15 mM
Hepes (Invitrogen Life Technologies), 10% (vol/vol) FCS and 50
M 2-ME (SigmaAldrich).
FTOC Media. RPMI 1640 supplemented with 100 units/ml peni-
cillin, 100 g/ml streptomycin, 2 mM Glutamax, 1 mM sodium
pyruvate, 15 mM Hepes, 10% (vol/vol) FCS, 50 M 2-ME, 0.5
mg/ml folic acid (Fluka), and 0.2 mg/ml glucose.
Quantitative RT-PCR. RNA was isolated from cells using the
RNeasy kit (Qiagen), and cDNA was synthesised using an
Omniscript kit (Qiagen) according to the manufacturer’s in-
structions with random hexamers (Invitrogen Life Technolo-
gies). Primers for quantitative analysis of RORt and IL-23R
mRNA were designed (refer to SI Methods). Quantitative RT-
PCR was performed using SYBR green (Applied Biosystems)
with 18S rRNA as the normalizer. The PCR conditions were
50°C for 2 min, 95°C for 10 min, followed by 40 cycles of 95°C
for 15 s, 60°C for 1 min, ending with a melting curve to validate
product specificity. Samples were run on a BIO RAD iQ5
Multicolor Real-time PCR Detection System.
Primers. RORt(F) TTGAGGAAACCAGGCATCCT;
RORt(R) CTGCAGAAACTGGGAATGCA; IL-23R(F) AG-
CAGGCCCTGTATGTGGAT; IL-23R(R) GTCCTGTGAGC-
CTTTCTTCTTTG.
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Fig. S1. RANTES and MIP-1 production by NKT cell subsets. RANTES and MIP-1 also were assessed as part of the larger cytokine analyses shown in Fig. 1. See
the legend of Fig. 1 for details. Cytokine values are expressed in pg/ml.
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Fig. S2. Distinct cytokine production by NKT cell subsets in response to-GalCer–pulsed DC. NKT cell subsets were isolated as described in Fig. 1. DC were purified
by sorting on CD11chi cells from spleen. DC then were incubated with 200-ng/ml -GalCer for 3 h before being washed twice and cultured with sorted NKT cell
subsets for 3 days. Cultures were set up with 5  104 NKT cells and 5  103 DCs per well in 100 l, and an aliquot of the supernatant was harvested at the time
points depicted to assay for cytokine production. IL-2, IL-5, IL-6, and RANTES were not detected in coculture supernatants, and MIP-1 and IL-21 were not tested.
Results represent 4 separate cultures derived during two independent experiments. For each experiment, tissues were pooled from 10–20 mice before
enrichment and sorting. Cells then were split between the individual cultures before being separately stimulated. Bars depict mean standard error. All cytokine
measurements are depicted in pg/ml.
Coquet et al. www.pnas.org/cgi/content/short/0801631105 3 of 6
Fig. S3. CD4NK1NKT cells from the lymph nodes, lung, and spleen are potent producers of IL-17. Lymphocytes from inguinal lymph nodes, lung, and spleen
were harvested from naı¨ve B6 mice. Lymphocytes were stimulated with PMA and ionomycin in the presence of GolgiStop for 3 h and were stained for
-GalCer/CD1d tetramer, CD4, NK1.1 and intracellular IL-17, and IFN-. Dot plots are gated on NKT cells or T cells (CD1d tetramer-TCR cells); numbers represent
the percentage of cells in that quadrant. Plots of lung NKT cells are pooled from three separate mouse lungs, and lymph node and spleen plots are pooled from
2 samples from a different experiment. Samples within each experiment were pooled after analysis using the ‘‘concatenate samples’’ function on FlowJo software
to represent the data better, because individual samples showed similar trends but had low numbers of events per sample. Lung and spleen NKT cells were from
1 experiment, and lymph node NKT cells were assayed in three independent experiments with similar results.
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Fig. S4. IL-17 production by NKT cells under Th17-inducing conditions. Bulk splenocytes were cultured with 100-ng/ml -GC for 3 d in the presence of various
factors including anti-IFN-, anti-IL-4, TGF-, and IL-6. After culture, cells were stained for -GC/CD1d tetramer, TCR, CD4 and intracellular IFN-, and IL-17.
(A) The left column depicts TCR versus -GC/CD1d tetramer expression in culture. The second column from the left depicts intracellular IFN- and IL-17
expression on gated NKT cells. The two rightmost columns are histograms of CD4 expression by IL-17 and IFN-NKT cells. (B) Graphical representation of results
fromA depicting the percentage of NKT cells in culture, the percentage of IL-17NKT cells, and the percentage of CD4 cells among IL-17NKT cells. Each circle
represents an individual mouse. Results shown are from 2 or three independent experiments.
Coquet et al. www.pnas.org/cgi/content/short/0801631105 5 of 6
Fig. S5. Cytokine production by CD4NK1.1 and CD4NK1.1 NKT cell subsets. NKT cells were isolated from thymuses and livers of young adult B6 mice. NKT
cells were identified as -GC/CD1d tetramer TCR cells and were divided further according to NK1.1 and CD4 expression. Purified NKT cell subsets were
cultured in wells coated overnight with 10-g/ml anti-CD3 and 10-g/ml anti-CD28, and an aliquot of supernatant was harvested at 24-h and 72-h time points
to assay for secreted cytokines. IL-17 was assayed by ELISA; all other cytokines were assayed by cytometric bead array. For thymus NKT cell subsets, the results
represent 7–8 separate cultures derived during four independent experiments. For liver NKT cell subsets, results represent 3–5 separate cultures derived during
two independent experiments. For each experiment, tissues were pooled from at least 10 mice prior to enrichment and sorting. Bars depict mean  standard
error. All cytokine values are expressed in pg/ml.
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